Table 1.
Patient characteristics
| Patients with HCL/HCLv and evidence of COVID-19 infection | 253 |
| Type of HCL | |
| Classic HCL | 238 |
| HCLv | 15 |
| Demographics | |
| Males | 202 |
| Females | 51 |
| Ages | 28-86 (median, 59) |
| Evidence for COVID-19 infection | |
| Positive COVID-19 test, either rapid-antigen test or PCR | 210 |
| No positive test, but nucleocapsid positive | 43 |
| COVID-19 symptoms | 36 |
| Asymptomatic | 7 |
| Year that patients tested positive for COVID-19 (n = 209) | |
| 2020 | 23 |
| 2021 | 46 |
| 2022 | 129 |
| 2023 | 12 |
| Patients who were untreated before testing positive for COVID-19 | 35 |
| Patients who were treated before testing positive for COVID-19 | 175 |
| Months from starting last treatment to testing positive for COVID-19 | 0.4-429 |
| Median mo from last treatment to testing positive for COVID-19 | 65.7 |
| Last treatment known | 175 |
| Bendamustine | 1 |
| Bendamustine-Rituximab | 5 |
| Binimetinib | 1 |
| BL22 anti-CD22 recombinant immunotoxin | 5 |
| Cladribine | 22 |
| Cladribine followed by rituximab within 6 mo | 11 |
| Cladribine with rituximab beginning the same wk (CDAR) | 45 |
| Dabrafenib-trametinib | 9 |
| Pentostatin followed by rituximab within 6 mo | 1 |
| Pentostatin-rituximab | 9 |
| Encorafenib-binimetinib | 4 |
| Fludarabine | 1 |
| Ibrutinib | 8 |
| Ibrutinib-rituximab | 1 |
| Interferon | 1 |
| Moxetumomab pasudotox | 15 |
| Moxetumomab pasudotox-obinutuzumab | 1 |
| Moxetumomab pasudotox-rituximab | 6 |
| RCHOP | 1 |
| Rituximab | 26 |
| Vemurafenib | 1 |
| Vemurafenib-obinutuzumab | 1 |
| Patients who received CD20 mAb before testing positive for COVID-19 | 132 |
| Months from last dose of CD20 mAb to COVID-19+ | 0.2-229 |
| Median months from last dose CD20 mAb to COVID-19+ | 62.7 |
| Vaccination status known | 253 |
| Not vaccinated | 28 |
| Vaccinated | 225 |
| Moderna | 77 |
| Pfizer | 110 |
| Johnson & Johnson | 6 |
| Sinovac | 1 |
| Combination | 31 |
| Of 210 HCL/HCLv patients who tested positive | |
| Vaccinated prior to testing positive | 160 |
| Days from first vaccination to testing positive: 17-810 (median 452) | |
| Moderna vaccine before testing positive | 56 |
| Pfizer vaccine before testing positive | 77 |
| Johnson & Johnson before testing positive | 3 |
| Combination before testing positive | 24 |
| Received a recognized specific treatment for COVID-19 | 70 |
| Convalescent plasma | 1 |
| Convalescent plasma and remdesivir | 3 |
| Bamlanivimab-etesevimab | 2 |
| Bebtelovimab | 2 |
| Casirivimab-imdevimab | 12 |
| Casirivimab-imdevimab, remdesivir, bebtelovimab | 1 |
| Sotrovimab | 4 |
| Tixagevimab-cilgavimab | 2 |
| Unknown mAb | 1 |
| Molnupiravir | 2 |
| Paxlovid | 39 |
| Remdesivir | 1 |
| No recognized specific treatment for COVID-19 | 140 |
| Disease severity in 210 HCL/HCLv patients testing positive | |
| Asymptomatic | 7 |
| Specific treatment | |
| None | 6 |
| Bamlanivimab-Etesevimab | 1 |
| Mild | 177 |
| Severe | 24 |
| Specific treatment | |
| None | 12 |
| Tixagevimab-cilgavimab | 1 |
| Unknown mAb | 1 |
| Paxlovid | 3 |
| Convalescent plasma | 1 |
| Casirivimab-imdevimab | 3 |
| Casirivimab-imdevimab, remdesivir, bebtelovimab | 1 |
| Convalescent plasma and remdesivir | 2 |
| Critical | 2 |
| Specific treatment: none | 2 |
CDAR, cladribine with immediate rituximab.